Millipore Sigma Vibrant Logo

440205 LY 83583 - CAS 91300-60-6 - Calbiochem

A cell-permeable, competitive inhibitor of soluble guanylate cyclase (IC₅₀ = 2 µM).

LY 83583 - CAS 91300-60-6 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: 6-Anilino-5,8-quinolinequinone

Primary Target: soluble guanylate cyclase
View This Product on Sigma-Aldrich
440205
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
91300-60-6C₁₅H₁₀N₂O₂

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
440205-5MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 5 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable, competitive inhibitor of soluble guanylate cyclase (IC50 = 2 µM). Lowers the production of cGMP levels in a wide range of tissues by blocking intracellular Ca2+ release, with negligible effect on cAMP levels. Inhibits nitric oxide-induced smooth muscle relaxation. Shown to inhibit interleukin-1-induced cGMP accumulation in cultured rat aortic vascular smooth muscle cells. Also inhibits neutrophil chemotaxis induced by NO donors.
      Catalogue Number440205
      Brand Family Calbiochem®
      Synonyms6-Anilino-5,8-quinolinequinone
      References
      ReferencesAdachi, R., et al. 2000. Int. J. Immunopharmacol. 22, 855.
      Kawada, T., et al. 1994. Gen. Pharmacol. 25, 1361.
      Beasley, D., et al. 1991. J. Clin. Invest. 87, 602.
      Pandol, S.J., et al. 1990. J. Biol. Chem. 265, 12846.
      Light, D.B., et al. 1989. Science 243, 383.
      Mulsch, A. 1988. J. Pharmacol. Exp. Ther. 247, 283.
      Fleisch, J.H., et al. 1984. J. Pharmacol. Exp. Ther. 229, 681.
      Product Information
      CAS number91300-60-6
      ATP CompetitiveN
      FormReddish purple solid
      Hill FormulaC₁₅H₁₀N₂O₂
      Chemical formulaC₁₅H₁₀N₂O₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetsoluble guanylate cyclase
      Primary Target IC<sub>50</sub>2 µM against soluble guanylate cyclase
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 22-36/37/38-45-46-48

      Harmful if swallowed.
      Irritating to eyes, respiratory system and skin.
      May cause cancer.
      May cause heritable genetic damage.
      Danger of serious damage to health by prolonged exposure.
      S PhraseS: 22-26-36/37/39-45

      Do not breathe dust.
      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, store in the refrigerator (4°C). Stock solutions are stable for up to 1 month at 4°C or up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      440205-5MGCN 04055977186727

      Documentation

      LY 83583 - CAS 91300-60-6 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      LY 83583 - CAS 91300-60-6 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      440205

      参考資料

      参考資料の概要
      Adachi, R., et al. 2000. Int. J. Immunopharmacol. 22, 855.
      Kawada, T., et al. 1994. Gen. Pharmacol. 25, 1361.
      Beasley, D., et al. 1991. J. Clin. Invest. 87, 602.
      Pandol, S.J., et al. 1990. J. Biol. Chem. 265, 12846.
      Light, D.B., et al. 1989. Science 243, 383.
      Mulsch, A. 1988. J. Pharmacol. Exp. Ther. 247, 283.
      Fleisch, J.H., et al. 1984. J. Pharmacol. Exp. Ther. 229, 681.

      カタログ

      タイトル
      Pathways and Biomarkers of Oxidative Stress
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision01-February-2024 JSW
      Synonyms6-Anilino-5,8-quinolinequinone
      DescriptionA cell-permeable, competitive inhibitor of soluble guanylate cyclase (IC50 = 2 µM). Lowers the production of cGMP levels in a wide range of tissues by blocking intracellular Ca2+ release, with negligible effect on cAMP levels. Inhibits nitric oxide-induced smooth muscle relaxation. Shown to inhibit interleukin-1-induced cGMP accumulation in cultured rat aortic vascular smooth muscle cells.
      FormReddish purple solid
      CAS number91300-60-6
      Chemical formulaC₁₅H₁₀N₂O₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityAcetone or Ethanol (3 mg/ml)
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, store in the refrigerator (4°C). Stock solutions are stable for up to 1 month at 4°C or up to 6 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      ReferencesAdachi, R., et al. 2000. Int. J. Immunopharmacol. 22, 855.
      Kawada, T., et al. 1994. Gen. Pharmacol. 25, 1361.
      Beasley, D., et al. 1991. J. Clin. Invest. 87, 602.
      Pandol, S.J., et al. 1990. J. Biol. Chem. 265, 12846.
      Light, D.B., et al. 1989. Science 243, 383.
      Mulsch, A. 1988. J. Pharmacol. Exp. Ther. 247, 283.
      Fleisch, J.H., et al. 1984. J. Pharmacol. Exp. Ther. 229, 681.